Urinary proteins, vitamin D and genetic polymorphisms as risk factors for febrile urinary tract infection and relation with bacteremia: a case control study.

by Willize E van der Starre, Cees van Nieuwkoop, Uginia Thomson, Marleen S M Zijderveld-Voshart, Jan Pieter R Koopman, Tanny J K van der Reijden, Jaap T van Dissel, Esther van de Vosse
Published 2015-01-01

Hospitalization for community-acquired febrile urinary tract infection: validation and impact assessment of a clinical prediction rule

by Janneke E. Stalenhoef, Willize E. van der Starre, Albert M. Vollaard, Ewout W. Steyerberg, Nathalie M. Delfos, Eliane M.S. Leyten, Ted Koster, Hans C. Ablij, Jan W. van’t Wout, Jaap T. van Dissel, Cees van Nieuwkoop
Published 2017-06-01

Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women

by Cees van Nieuwkoop, Willize E. van der Starre, Janneke E. Stalenhoef, Anna M. van Aartrijk, Tanny J. K. van der Reijden, Albert M. Vollaard, Nathalie M. Delfos, Jan W. van ’t Wout, Jeanet W. Blom, Ida C. Spelt, Eliane M. S. Leyten, Ted Koster, Hans C. Ablij, Martha T. van der Beek, Mirjam J. Knol, Jaap T. van Dissel
Published 2017-04-01